Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomustine Combined With Anlotinib in Extensive-stage Small Cell Lung Cancer
NCT07632209Phase 2Not yet recruiting
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
A Phase 2 trial of lomustine, anlotinib in small cell lung cancer (SCLC). Planned start Jun 2026; status: not yet recruiting.
02
Drugs
lomustineanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07632209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07632209.